Archives
GlycoRNA–RBP Domains and TAT Cell Entry
2026-09-09
The reference study reports that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanoclusters that support entry of the cell-penetrating peptide TAT. Its perturbation experiments connect RNA-dependent surface organization with peptide uptake, expanding the working definition of the plasma membrane while leaving the molecular assembly pathway and broader generality open for further study.
Angiotensin II Workflows for Vascular Research
2026-09-09
Build reproducible Angiotensin II assays for receptor signaling, oxidative stress, vascular smooth muscle cell hypertrophy, and aneurysm modeling. This guide separates acute cell stimulation from chronic in vivo exposure and translates a targeted AAA nanomedicine study into practical assay-design choices.
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-09-08
This 2024 case report shows that prochlorperazine can precipitate neuroleptic malignant syndrome (NMS) at a standard prescribed dose, even when creatine phosphokinase and other routine laboratory findings are not markedly abnormal. The practical implication is that medication history, rigidity, fever, autonomic instability, and mental-status change should guide urgent diagnosis and treatment rather than laboratory abnormalities alone.
Rucaparib (AG-014699): PARP1 Research Guide
2026-09-08
Rucaparib, also called AG-014699 or PF-01367338, is a PARP1 inhibitor used in DNA damage response and cancer biology research. Its reported activity, repair-deficient model sensitivity, formulation properties, and transporter behavior support controlled in vitro and translational laboratory studies.
Tivozanib (AV-951): From Target to Phenotype
2026-09-07
Tivozanib and AV-951 offer a precise model for connecting VEGFR signaling pathway inhibition with measurable cancer-cell phenotypes. This article presents a mechanism-to-phenotype framework that separates cytostasis, cell killing, and anti-angiogenic effects for more interpretable oncology assays.
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-07
Build reproducible fluorescence, western blot, and flow cytometry workflows around a Cy3-labeled secondary antibody that amplifies mouse primary-antibody signals. The approach is especially useful for testing PMCA4b-dependent aldosterone signaling while preserving practical controls for specificity, storage, and spectral optimization.
Caspase-3 Colorimetric Assay Kit: Practical Guide
2026-09-05
The Caspase-3 Colorimetric Assay Kit (SKU K2008) provides a lysate-based method for measuring DEVD-dependent caspase-3 activity through release of p-nitroaniline at 405 or 400 nm. It is appropriate for prepared biological samples and apoptosis studies, but not for direct live-cell imaging or unprocessed complex tissues; this guide is based on the product dossier and workflow best practices rather than directly matched paper evidence.
Vidarabine Monohydrate: From Mechanism to Translation
2026-09-04
Vidarabine monohydrate is more than a catalog entry: it is a mechanistic probe for studying adenosine-mimetic disruption of viral DNA synthesis. This thought-leadership guide connects assay design, formulation discipline, translational evidence standards, and a carefully bounded lesson from recent SERT–nNOS research.
Cathepsin B inhibitor CA-074: Protocol Guide
2026-09-04
CA-074 (SKU A1926) provides selective cathepsin B inhibition for biochemical, cell-based, and disease-model workflows where separation from cathepsins H and L is important. This guide covers solvent selection, controls, storage, and interpretation boundaries; it is not appropriate as a broad-spectrum cysteine protease inhibitor or as evidence for outcomes beyond the supplied product dossier.
Caspase-3 Colorimetric Assay Kit in Macrophages
2026-09-03
Use the Caspase-3 Colorimetric Assay Kit to add a quantitative apoptosis layer to macrophage infection, ER-stress, and inflammatory-response studies. Its DEVD-pNA endpoint works with standard plate readers, providing a practical complement to ROS, pathway, and bacterial-clearance measurements.
Rotigotine Transdermal Delivery in PD and RLS
2026-09-03
The reference review explains how Rotigotine’s lipid solubility, receptor pharmacology, and rapid oral metabolism led to development of a transdermal system designed to provide continuous dopaminergic stimulation. It connects pharmacokinetic reasoning with clinical evidence for motor benefit in early- and advanced-stage Parkinson’s disease and symptom improvement in moderate-to-severe restless legs syndrome.
Imipenem: Linking PBPs to Resistance Assays
2026-09-02
Imipenem is a semisynthetic thienamycin antibiotic with a distinctive role in antibacterial research. This article connects its PBP mechanism with carbapenemase-gene localization, transfer assays, and immune-response experiments to improve interpretation of resistance studies.
DIDS: Reliable Cell Assay Design
2026-09-02
This scenario-based guide explains how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid), SKU B7675, can be incorporated into cell viability, proliferation, cytotoxicity, and mechanistic ion-transport studies. It emphasizes solvent control, model-specific IC50 interpretation, orthogonal validation, and practical product-selection criteria.
SW033291: PGE2 Signaling for Regeneration
2026-09-01
SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue repair. This article translates new muscle-regeneration findings into practical assay decisions while clarifying what the compound can—and cannot—establish experimentally.
Glucose Uptake as a Lens on Sorafenib Resistance
2026-09-01
A translational framework for using fluorescence-based glucose uptake measurements to contextualize lipid reprogramming, ferroptosis, and sorafenib resistance in hepatocellular carcinoma without overstating what a single metabolic readout can prove.
3653 records 9/244 page Previous Next First page 上5页 678910 下5页 Last page